ORPH
Orphazyme A/S
Set alert
52-week range unavailable
- Open
- 0.906
- Prev close
- 0.87
- Mkt cap
- 37.27M
- Vol
- 941.41K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8457
- High
- 0.955
- Forward P/E
- -0.53
- Beta
- 0.80
- Short ratio
- 0.78
- Inst. own
- 3.80%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.39
- 200-d avg
- 3.45
- 1y target
- 1.00
Key statistics
- Market cap
- 37.27M
- Enterprise value
- -250.04M
- Trailing P/E
- 0.00
- Forward P/E
- -0.53
- PEG ratio
- 0.00
- Price / sales
- 2.83
- Price / book
- 0.18
- EPS (TTM)
- -3.83
- Beta
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 13.15M
- Revenue growth
- 0.00%
- Free cash flow
- -392.38M
- Total cash
- 334.18M
- Total debt
- 58.59M
- Return on equity
- -251.34%
- Shares outstanding
- 35.31M
- Short % of float
- 0.00%
- 50-day average
- 1.39
- 200-day average
- 3.45
Analyst view
Consensus: sell
- Strong buy0
- Buy0
- Hold0
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 30, 2021 | B of A Securities | down | Neutral | Underperform |
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- orphazyme.com
News
- Orphazyme Announces Publication of 2022 Financial Results and Annual Report
- Orphazyme reports financial results in Interim Report First Half 2022
- Orphazyme Announces Publication of 2021 Financial Results and Annual Report
- Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
- Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
- Orphazyme announces update on in-court restructuring proceedings
- Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
- Dear ORPH Stock Fans, Mark Your Calendars for March 31
- Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
- Orphazyme A/S has filed for voluntary delisting of ADSs
Your note
Sign in to keep a note on ORPH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.77% | 271,994 | 655.50K | Dec 30, 2021 |
| Geode Capital Management, LLC | 0.50% | 177,074 | 426.75K | Dec 30, 2021 |
| Two Sigma Investments, LP | 0.40% | 141,117 | 340.09K | Dec 30, 2021 |
| Profund Advisors LLC | 0.36% | 127,524 | 307.33K | Dec 30, 2021 |
| Susquehanna International Group, LLP | 0.32% | 114,372 | 275.64K | Dec 30, 2021 |
| Optiver Holding B.v. | 0.30% | 106,836 | 257.47K | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index ETF | 0.44% | 154,926 | 306.75K | Jan 30, 2022 |
| ProFunds-VP Europe 30 | 0.31% | 109,548 | 264.01K | Dec 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 21,566 | 51.97K | Dec 30, 2021 |